Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.57 USD | +0.31% | +0.53% | +0.04% |
05:35am | Sanofi Invites Initial Bids for $20 Billion Consumer Spinoff | MT |
25/06 | Biotech Firm Clario Eyes IPO Early in 2025 | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Investment Banking & Brokerage Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.04% | 159B | - | ||
+18.56% | 155B | C+ | ||
+7.41% | 135B | B- | ||
+19.71% | 117B | C+ | ||
-11.05% | 34.4B | B+ | ||
+9.14% | 25.22B | B | ||
+21.25% | 20.62B | B+ | ||
-14.35% | 18.6B | B+ | ||
+47.28% | 17.28B | B | ||
+3.74% | 15.48B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MS Stock
- MS.PRL Stock
- Ratings Morgan Stanley